Related Experiment Videos
A cautionary case: the SynerGraft vascular prosthesis
M A Sharp1, D Phillips, I Roberts
1Nuffield Department of Surgery, John Radcliffe Hospital, Oxford, UK.
Summary
New SynerGraft vascular prostheses show potential for arterial reconstruction but require caution. Early aneurysmal degeneration in a femoral-posterior tibial bypass case highlights the need for further human data.
Area of Science:
- Vascular Surgery
- Biomaterials Science
- Regenerative Medicine
Background:
- Autologous conduits remain the gold standard for small diameter arterial reconstruction.
- Existing synthetic vascular prostheses often face challenges like thrombosis and infection.
- The SynerGraft xenograft prosthesis was developed to overcome limitations of previous glutaraldehyde-treated grafts.
Observation:
- A 68-year-old male patient with acute limb ischemia underwent a femoral-posterior tibial bypass using two 50 cm SynerGraft prostheses.
- The patient presented with aneurysmal degeneration along the graft's course at 8 weeks post-operation.
Findings:
- The SynerGraft xenograft prosthesis, intended for small diameter arterial reconstruction, exhibited aneurysmal degeneration in a clinical case.
- This adverse outcome occurred despite the prosthesis's claimed improvements over earlier generations of synthetic grafts.
Implications:
- Clinical use of the SynerGraft prosthesis warrants caution due to the observed early graft complication.
- Further clinical studies and long-term data are essential to validate the safety and efficacy of this xenograft in humans.
- The findings suggest potential limitations of current xenograft technology in vascular reconstruction, necessitating ongoing research and development.